Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Early research (Phase 1)Study completedNCT04846920
What this trial is testing

Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT03634540
What this trial is testing

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Who this might be right for
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 118
Large-scale testing (Phase 3)Active Not RecruitingNCT05899049
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 251
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Study completedNCT03216499
What this trial is testing

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

Who this might be right for
Recurrent Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Testing effectiveness (Phase 2)Study completedNCT04489771
What this trial is testing

Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 154
Large-scale testing (Phase 3)Active Not RecruitingNCT04195750
What this trial is testing

Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 755
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Not applicableStudy completedNCT07025291
What this trial is testing

Assessment of Salivary Biomarker Levels in Individuals With Various Periodontal Diseases

Who this might be right for
Periodontal Diseases
Izmir Katip Celebi University 60
Early research (Phase 1)Study completedNCT06919991
What this trial is testing

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Who this might be right for
Healthy Participants
Arcus Biosciences, Inc. 14
Early research (Phase 1)Active Not RecruitingNCT05030506
What this trial is testing

Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT05468697
What this trial is testing

Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 60
Early research (Phase 1)Study completedNCT05117554
What this trial is testing

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Who this might be right for
Healthy Participants
Arcus Biosciences, Inc. 70
Testing effectiveness (Phase 2)Ended earlyNCT05119335
What this trial is testing

NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
ccRCCClear Cell Renal Cell CarcinomaKidney Cancer+14 more
NiKang Therapeutics, Inc. 120